IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Licensing/Co-Marketing Agreements
Marketed Products
Product Class Date Terms of Agreement
Exforge (valsartan +
amlodipine)
C 2009 Co-promotion agreement for France with Ipsen.
Galvus (vildagliptin) A 2008 Novartis Korea and HANDOK signed a co-promotion deal
for South Korea.
Simulect (basiliximab) L 2006 Cerimon acquired exclusive worldwide rights to
basiliximab for the treatment of inflammatory bowel
disease.
Lescol (fluvastatin) and
Lescol XL (fluvastatin
extended release)
C 1993-
2008
Elidel (pimecrolimus) L 2004-
6
Was co-marketed with Mitsubishi Tanabe in Japan under
the terms of a 1993 deal, but this deal was terminated in
2008. AstraZeneca has rights in a number of markets. In
2001, German rights were licensed to Klinge and Fournier,
which is now part of Solvay. In 2006, Biovail licensed-in
rights to market Lescol and Lescol XL in Canada until
2008, and LG Pharma agreed to co-market the product in
South Korea with Novartis.
In 2004, Avantec Vascular obtained an option to license
pimecrolimus for use in its drug-eluting stents. In 2006,
Conor Medsystems obtained worldwide, non-exclusive
license to pimecrolimus for use with its next-generation
controlled vascular drug delivery technologies.
Enablex (darifenacin) G 2005 Deal with Procter & Gamble for the co-promotion and
further development of Enablex extended release tablets
for the treatment of overactive bladder in the USA.
Cibacen
(benazepril)/Cibadrex
(benazepril + HCT)
C 2005 Meda AB granted exclusive rights in most European
markets.
Cubicin (daptomycin) J 2003 Chiron (now part of Novartis) acquired rights in Western
Europe, Eastern Europe, the Middle East, Australia, New
Zealand, Central America, South America and India.
Certican (everolimus) L 2002 Novartis licensed everolimus to Guidant for use in
Guidant’s stents. Later revised to give Guidant exclusivity,
and the right to grant sub-licenses.
© 2009 IMS Health In cor po rated or its af fil i ates Page 124